Inhibrx has been granted a patent for a multispecific polypeptide construct with constrained CD3 binding, featuring dual effector functions upon cleavage. The construct includes specific components and linkers for therapeutic, diagnostic, and prophylactic applications. GlobalData’s report on Inhibrx gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Inhibrx, Personalized cancer vaccines was a key innovation area identified from patents. Inhibrx's grant share as of January 2024 was 27%. Grant share is based on the ratio of number of grants to total number of patents.
Multispecific polypeptide construct with dual effector functions
See Also:
A recently granted patent (Publication Number: US11866507B2) discloses a multispecific polypeptide construct designed for therapeutic purposes. The construct consists of a first component with a heterodimeric immunoglobulin Fc region and a second component with a CD3-binding region. These components are linked by specific polypeptides, with the CD3-binding region being an anti-CD3 disulfide stabilized Fv antibody fragment. The construct also includes antigen binding domains that bind to tumor-associated antigens, enhancing its therapeutic potential. Importantly, the CD3-binding region's ability to bind cell surface CD3 is dependent on the antigen binding domain being bound to its target antigen, as determined by flow cytometry.
Furthermore, the patent details various embodiments of the multispecific polypeptide construct, including different tumor-associated antigens that can be targeted, such as 5T4, B7H3, EGFR, and Folate receptor alpha (FRa). The construct's linkers are composed of specific amino acid residues, enhancing its stability and functionality. Additionally, the patent covers the inclusion of the multispecific polypeptide construct in pharmaceutical compositions along with a pharmaceutically acceptable carrier, paving the way for potential therapeutic applications in the treatment of various diseases. Overall, the patent highlights the innovative design and potential therapeutic utility of the multispecific polypeptide construct in targeting specific antigens for therapeutic intervention.
To know more about GlobalData’s detailed insights on Inhibrx, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
